Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;51(5):449-476.
doi: 10.1007/s10928-024-09922-x. Epub 2024 May 1.

Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins

Affiliations

Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins

Shufang Liu et al. J Pharmacokinet Pharmacodyn. 2024 Oct.

Abstract

Two-pore physiologically based pharmacokinetic (PBPK) modeling has demonstrated its potential in describing the pharmacokinetics (PK) of different-size proteins. However, all existing two-pore models lack either diverse proteins for validation or interspecies extrapolation. To fill the gap, here we have developed and optimized a translational two-pore PBPK model that can characterize plasma and tissue disposition of different-size proteins in mice, rats, monkeys, and humans. Datasets used for model development include more than 15 types of proteins: IgG (150 kDa), F(ab)2 (100 kDa), minibody (80 kDa), Fc-containing proteins (205, 200, 110, 105, 92, 84, 81, 65, or 60 kDa), albumin conjugate (85.7 kDa), albumin (67 kDa), Fab (50 kDa), diabody (50 kDa), scFv (27 kDa), dAb2 (23.5 kDa), proteins with an albumin-binding domain (26, 23.5, 22, 16, 14, or 13 kDa), nanobody (13 kDa), and other proteins (110, 65, or 60 kDa). The PBPK model incorporates: (i) molecular weight (MW)-dependent extravasation through large and small pores via diffusion and filtration, (ii) MW-dependent renal filtration, (iii) endosomal FcRn-mediated protection from catabolism for IgG and albumin-related modalities, and (iv) competition for FcRn binding from endogenous IgG and albumin. The finalized model can well characterize PK of most of these proteins, with area under the curve predicted within two-fold error. The model also provides insights into contribution of renal filtration and lysosomal degradation towards total elimination of proteins, and contribution of paracellular convection/diffusion and transcytosis towards extravasation. The PBPK model presented here represents a cross-modality, cross-species platform that can be used for development of novel biologics.

Keywords: Albumin; Antibody fragments; Monoclonal antibody; Physiologically based pharmacokinetic (PBPK) modeling; Protein therapeutics; Two-pore theory.

PubMed Disclaimer

Conflict of interest statement

Declarations Competing interests The authors declare no competing interests.

Similar articles

Cited by

References

    1. Jin S et al (2022) Emerging new therapeutic antibody derivatives for cancer treatment. Signal Transduct Target Ther 7(1):39 - PubMed - PMC
    1. Zaman R et al (2019) Current strategies in extending half-lives of therapeutic proteins. J Control Release 301:176–189 - PubMed
    1. AlQahtani AD et al (2019) Strategies for the production of long-acting therapeutics and efficient drug delivery for cancer treatment. Biomed Pharmacother 113:108750 - PubMed
    1. Boswell CA et al (2010) Effects of charge on antibody tissue distribution and pharmacokinetics. Bioconjug Chem 21(12):2153–2163 - PubMed
    1. Li Z, Krippendorff BF, Shah DK (2017) Influence of Molecular size on the clearance of antibody fragments. Pharm Res 34(10):2131–2141 - PubMed - PMC

LinkOut - more resources